Oculis and EURETINA Announce Ramin Tadayoni Award

ZUG, Switzerland, June 27, 2024 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) has announced the establishment of the Ramin Tadayoni Award in collaboration with EURETINA. The award is named in memory of the company's late Chief Scientific Officer, Professor Ramin Tadayoni, who was a globally recognized retina specialist.

The Ramin Tadayoni Award, supported by Oculis and managed by EURETINA, will be an annual honor that includes €30,000 for research support and an additional €5,000 for the recipient. This award aims to recognize emerging ophthalmologists showing exceptional promise in retina research. Applications will be open in June and July 2024, with the first award presented at the EURETINA Congress in September.

Riad Sherif, M.D., CEO of Oculis, expressed his admiration for Professor Tadayoni, highlighting his significant contributions to the company and the field of ophthalmology. He noted that Tadayoni was not only a scientific luminary but also known for his kindness and mentorship. Sherif emphasized that the award would continue Tadayoni's legacy of advancing retinal research and improving patient care.

Anat Loewenstein, M.D., President of EURETINA, echoed these sentiments, stating that the award honors Professor Tadayoni’s remarkable impact on ophthalmic research. She highlighted the importance of investing in the next generation of ophthalmologists to continue driving innovation and excellence in retinal care.

During his career, Professor Tadayoni held prominent positions, including President of EURETINA, Chairman of the Retina Department at Rothschild Foundation Hospital, and Chairman of the French Myopia Institute. He was also Chief of the Department for Lariboisière university hospitals and Saint-Louis hospital and a Professor of Ophthalmology at University Paris-Cité. His consultancy roles in the ophthalmology industry and his chairmanship of Oculis’ Retina Scientific Advisory Board underscored his influence in the field.

Professor Tadayoni contributed extensively to medical research, authoring over 320 scientific articles and contributing to numerous ophthalmology textbooks. His achievements were recognized by several prestigious awards, including the American Academy of Ophthalmology Achievement Award and the Jules Gonin Award from the Retina Research Foundation.

Professor Tadayoni’s academic credentials include a medical degree and internship at Paris V University, a retina fellowship at Lariboisière University Hospital, and a Ph.D. in Science from Paris VII University and the Paris Vision Institute.

Oculis Holding AG is dedicated to saving sight and enhancing eye care through its innovative biopharmaceutical developments. The company's product pipeline includes OCS-01, a topical eye drop for diabetic macular edema and post-cataract surgery inflammation; OCS-02, a biologic anti-TNFα eye drop candidate for dry eye disease and non-infectious anterior uveitis; and OCS-05, a candidate for acute optic neuritis. Headquartered in Switzerland, with operations in the U.S. and Iceland, Oculis is committed to improving health and quality of life globally, supported by a seasoned management team and top international healthcare investors.